Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ARTN is a subtype of the glial cell-derived neurotrophic factor (GDNF) family of ligands (GFL). It mainly mediates the survival, differentiation, and migration of various types of neurons. GFRα3, one of ARTN and its receptor, is highly expressed in malignant tumors and plays a role in the development of various malignant tumors. Studying the mechanism of action of ARTN in malignant tumors can help early diagnosis, treatment and prognosis of tumors, and may be a powerful theoretical basis for guiding targeted therapy of malignant tumors.
The glial cell line-derived neurotrophic factor (GDNF) belongs to the TFGβ superfamily, and its ligand includes four members. ARTN is the last member of the GDNF family. The primary structure of ARTN is similar to GDNF, NTN, and PSP. It has a full length of 3.9 kb and the encoded protein consists of 220 amino acids. Members of the GDNF family need to bind to their respective high-affinity receptors and then bind to a common signaling molecule, RET. Then, phosphorylation of RET is activated to activate different intracellular pathways that regulate physiological processes such as cell growth, differentiation, proliferation, and migration.
Fig 1. GDNF family of ligands and their receptors. (Kramer, et al. 2015)
The Role of ARTN in the Development of Neural Tissue
ARTN plays different roles in the different stages of differentiation, survival and growth of sympathetic neurons. Studies have observed the effect of ARTN on the passage, survival and growth of the cervical and thoracic paraspinal ganglia in the embryonic and postnatal rats. The study found that ARTN can promote the differentiation of sympathetic neural stem cells and increase the passage of new neurons. ARTN supports the survival of dopaminergic neurons. An in vitro experiment injected NBN/ARTN or GDNF chronic viral vector cDNA into the nigrostriatal and ventral midbrain. After 3 weeks, only 20% of the nigrostria in the control group survived, while NBN/ARTN and GDNF group have 80% to 90% survive. It can be seen that NBN/ARTN is similar to GDNF and is a powerful neuroprotective factor for nigrostriatal dopaminergic neurons. In addition, ARTN is a strong inducer of intestinal hematopoietic cells. The ARTN receptor pathway promotes the formation of Peyre’s Patch, a major component of the gut-associated lymphoid tissue.
ARTN and Cancer
ARTN is an oncogene for breast cancer, and ARTN is expressed in a variety of breast cancer cell lines and breast cancer tissues. As the degree of malignancy increases, ARTN expression increases. Cell experiments confirmed that up-regulation of ARTN expression levels can increase the non-adherent growth of breast cancer cells and increase the number of cell population formation. Moreover, it can promote the formation of tumor cell phenotype and increase the invasion and metastasis of breast cancer tumor cells. ARTN promotes tumor growth by activating Twist1-VEGF-A channel partially mediated VEGF-A to promote neovascularization. Ding et al. found that ARTN mediates the acquired resistance to trastuzumab in HER2-positive breast cancer and reduces the sensitivity of trastuzumab in the treatment of breast cancer.
Liver cancer is one of the top ten malignant tumors in the world. ARTN is highly expressed in hepatocellular carcinoma cell lines. In vitro, ARTN can promote the growth, migration, and inhibition of hepatoma cells. In the mouse tumor formation experiment, the ARTN overexpressing cell line not only formed a larger tumor but also more invasive. In pathological studies, ARTN is associated with prognosis in patients with liver cancer. ARTN is expected to be a target for the diagnosis and treatment of liver cancer, providing new ideas and methods for the treatment of liver cancer. Zhang et al. identified a novel HIF-1α/ARTN axis that promotes CSC (hypoxia-regulated cancer stem cell)-like behavior in an anoxic environment, suggesting that ARTN is a valuable therapeutic target for HCC.
Pancreatic cancer is a highly malignant tumor with a very poor prognosis. Gao et al found that ARTN can promote the aggressiveness and neurotrophic function of pancreatic cancer in vivo and in vitro. Therefore, Artemin can be used as a new therapeutic target for pancreatic cancer. In the study, the expression of ARTN and its receptor GFRα3 /RET in pancreatic ductal adenocarcinoma and normal tissues were analyzed by Western blot. The expression of ARTN mRNA in pancreatic and cancer cell lines was detected by QRT-PCR. The results suggest that ARTN and receptor GFRα3 /RET can be detected in pancreatic cancer tissues and cell lines, and distributed along the nerve and blood vessel walls to promote cancer cell infiltration.
The tumorigenicity of ARTN is also manifested in endometrial cancer. Studies have shown that the expression of ARTN protein in endometrial cancer tissues is significantly higher than that in normal endometrial tissues, which is positively correlated with tumor stage and infiltration. In the allograft model, up-regulation of ARTN expression can increase tumor size, promote tumor invasion, hyperproliferation, and low differentiation. These effects of ARTN are mediated by AKT1, and small interfering RNA (siRNA) can inhibit the tumorigenic effects of ARTN. Wang et al. examined the differential expression of ARTN and matrix metalloproteinase protein 9 (MMP-9) in endometrial carcinoma (EC), indicating that ARTN and MMP-9 are involved in the development, progression, invasion, and metastasis of EC.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.